Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies
作者： Pedro Esbrit , María José Alcaraz
DOI: 10.1016/J.BCP.2013.03.002
关键词:
摘要: Osteoporosis is characterized by low bone mineral density and/or poor microarchitecture leading to an increased risk of fractures. The skeletal alterations in osteoporosis are a consequence relative deficit formation compared resorption. therapies have mostly relied on antiresorptive drugs. An alternative therapeutic approach for currently available, based the intermittent administration parathyroid hormone (PTH). Bone anabolism caused PTH therapy mainly accounted ability increase osteoblastogenesis and osteoblast survival. PTH-related protein (PTHrP)-an abundant local factor bone- interact with common type 1 receptor similar affinities osteoblasts. Studies rodent models limited data postmenopausal women suggest that N-terminal PTHrP peptides might be considered promising anabolic therapy. In addition, putative osteogenic actions ascribed not only its domain but also PTH-unrelated C-terminal region. this review, we discuss underlying cellular molecular mechanisms potential (PTHrP) mass improve regeneration.
elsevier.com
sci-hub.se 参考文章(74)
N. E. Cusano, A. G. Costa, B. C. Silva, S. Kousteni, J. P. Bilezikian, Catabolic and anabolic actions of parathyroid hormone on the skeleton. Journal of Endocrinological Investigation. ,vol. 34, pp. 801- 810 ,(2011) , 10.3275/7925
Pedro Esbrit, Sergio Portal-Núñez, Daniel Lozano, Role of angiogenesis on bone formation. Histology and Histopathology. ,vol. 27, pp. 559- 566 ,(2012) , 10.14670/HH-27.559
Diane Gesty-Palmer, Louis M. Luttrell, 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? British Journal of Pharmacology. ,vol. 164, pp. 59- 67 ,(2011) , 10.1111/J.1476-5381.2011.01450.X
Robert L. Jilka, Maria Almeida, Elena Ambrogini, Li Han, Paula K. Roberson, Robert S. Weinstein, Starros C. Manolagas, Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration Aging Cell. ,vol. 9, pp. 851- 867 ,(2010) , 10.1111/J.1474-9726.2010.00616.X
D Lozano, L Fernández-de-Castro, S Portal-Núñez, A López-Herradón, S Dapía, E Gómez-Barrena, P Esbrit, The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low-turnover osteopaenia British Journal of Pharmacology. ,vol. 162, pp. 1424- 1438 ,(2011) , 10.1111/J.1476-5381.2010.01155.X
A. F. Stewart, R. L. Cain, D. B. Burr, D. Jacob, C. H. Turner, J. M. Hock, Marc K. Drezner, Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. Journal of Bone and Mineral Research. ,vol. 15, pp. 1517- 1525 ,(2000) , 10.1359/JBMR.2000.15.8.1517
Steven L. Teitelbaum, Margaret P. Seton, Kenneth G. Saag, Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis & Rheumatism. ,vol. 63, pp. 325- 328 ,(2011) , 10.1002/ART.30135
Antonio J. Salinas, Pedro Esbrit, María Vallet-Regí, A tissue engineering approach based on the use of bioceramics for bone repair Biomaterials Science. ,vol. 1, pp. 40- 51 ,(2013) , 10.1039/C2BM00071G
Marit D Moen, Lesley J Scott, Recombinant Full-Length Parathyroid Hormone (1–84) Drugs. ,vol. 66, pp. 2371- 2381 ,(2006) , 10.2165/00003495-200666180-00008
Matthew Schnoke, Sharon B. Midura, Ronald J. Midura, Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair Bone. ,vol. 45, pp. 590- 602 ,(2009) , 10.1016/J.BONE.2009.05.006